dc.contributor.author |
Fernandez-Martinez, Aranzazu |
dc.contributor.author |
Pascual, Tomás |
dc.contributor.author |
Perrone, Giuseppe |
dc.contributor.author |
Morales Murillo, Serafín |
dc.contributor.author |
de la Haba, Juan |
dc.contributor.author |
González-Rivera, Milagros |
dc.contributor.author |
Galván, Patricia |
dc.contributor.author |
Zalfa, Francesca |
dc.contributor.author |
Amato, Michela |
dc.contributor.author |
Gonzalez, Lucia |
dc.contributor.author |
Prats, Miquel |
dc.contributor.author |
Rojo, Federico |
dc.contributor.author |
Manso, Luis |
dc.contributor.author |
Paré, Laia |
dc.contributor.author |
Alonso, Immaculada |
dc.contributor.author |
Albanell, Joan |
dc.contributor.author |
Vivancos, Ana |
dc.contributor.author |
González, Antonio |
dc.contributor.author |
Matito, Judit |
dc.contributor.author |
González, Sonia |
dc.contributor.author |
Fernandez, Pedro |
dc.contributor.author |
Adamo, Barbara |
dc.contributor.author |
Muñoz, Montserrat |
dc.contributor.author |
Viladot, Margarita |
dc.contributor.author |
Font, Carme |
dc.contributor.author |
Aya, Francisco |
dc.contributor.author |
Vidal, Maria |
dc.contributor.author |
Caballero, Rosalía |
dc.contributor.author |
Carrasco, Eva |
dc.contributor.author |
Altomare, Vittorio |
dc.contributor.author |
Tonini, Giuseppe |
dc.contributor.author |
Prat, Aleix |
dc.contributor.author |
Martin, Miguel |
dc.date |
2021-03-24T07:50:34Z |
dc.date |
2021-03-24T07:50:34Z |
dc.date |
2017 |
dc.identifier |
1949-2553 |
dc.identifier |
http://hdl.handle.net/10459.1/70874 |
dc.identifier |
https://doi.org/10.18632/oncotarget.15748 |
dc.identifier.uri |
http://hdl.handle.net/10459.1/70874 |
dc.description |
PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%. |
dc.description |
This work was supported by funds from Instituto de Salud Carlos III - PI13/01718 (AP), FEDER/ RETICC-RD12/0036/0076 (MM) and FEDER/RETICCRD12/0036/0051 (JA), a Career Catalyst Grant from the Susan Komen Foundation (AP), by Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (AP), by Banca d’Italia (GP) and by T.C.I. telecomunicazioni (GP) |
dc.language |
eng |
dc.publisher |
Impact Journals |
dc.relation |
Reproducció del document publicat a https://doi.org/10.18632/oncotarget.15748 |
dc.relation |
Oncotarget, 2017, vol. 8, núm. 13, p, 21930-21937 |
dc.rights |
cc-by (c) Fernandez-Martinez et al., 2017 |
dc.rights |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
PAM50/Prosigna |
dc.subject |
Breast cancer |
dc.subject |
Ki67 |
dc.subject |
Estrogen receptor-positive/HER2-negative |
dc.title |
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |